Aethlon Medical Publishes In Vitro Studies Demonstrating Hemopurifier Resin Binding of Seven Clinically Relevant COVID-19 Variants

Viral capture efficiency ranged from 53% to 89% for the seven COVID-19 variants tested SAN DIEGO, May 2, 2022 /PRNewswire/ — Aethlon Medical, Inc. (Nasdaq: AEMD), a medical technology company focused on developing products to diagnose and treat life and organ threatening diseases, today…

Click here to view original post